FDA Approves Camizestrant for ESR1-Mutated Breast Cancer M. Alexander Otto, PA, MMSc

https://www.medscape.com/viewarticle/fda-approves-camizestrant-esr1-mutated-breast-cancer-2026a1000x85?src= The FDA has granted accelerated approval to camizestrant (Etcamah, AstraZeneca), in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, on the basis of an FDA-authorized test.